PT-141 (Bremelanotide): what the human research actually shows
A real FDA-approved peptide with a narrow, specific indication and a modest effect. Most of the public-facing hype around PT-141 has little to do with the population it was actually approved for.
Why I looked into this
PT-141 shows up constantly in the men’s-health corners of the internet as a quiet alternative to PDE5 inhibitors. It is almost never discussed as what it actually is: an FDA-approved on-demand product for premenopausal women with a specific sexual desire disorder, not a general-purpose libido peptide for anyone who wants one.
I wanted to separate what the RECONNECT trials actually showed from the marketing layer that has grown on top of the drug. The gap between the approved indication and the way PT-141 is talked about online is one of the widest on my list.
What PT-141 actually is
PT-141, generic name bremelanotide, is a synthetic seven-amino-acid cyclic peptide. It is a non-selective agonist at melanocortin receptors, with activity at the MC4 receptor thought to drive its effect on sexual motivation and arousal. It was originally derived from Melanotan II (a tanning peptide) during research into melanocortin pathways.
Developed by Palatin Technologies and later co-marketed with AMAG Pharmaceuticals before reverting to Palatin in 2020, bremelanotide was approved by the FDA in June 2019 under the brand name Vyleesi. The approved product is a single-use subcutaneous autoinjector used on-demand, at least 45 minutes before anticipated sexual activity.
What the human research shows
Do published human trials exist?
Yes, and the registration dossier is unusually clean to read.
Vyleesi was approved on the basis of two identical pivotal Phase 3 randomized, double-blind, placebo-controlled trials, run together as the RECONNECT program. Combined enrollment was 1,247 premenopausal women with acquired, generalized hypoactive sexual desire disorder. The primary endpoints were improvement in sexual desire (measured by the FSFI-D) and decrease in distress related to sexual function (measured by item 13 of the FSDS-DAO). Industry funded by AMAG Pharmaceuticals and Palatin Technologies.
What evidence actually exists?
The most important trials to know:
- Kingsberg SA, Clayton AH, Portman D, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstetrics and Gynecology. 2019;134(5):899-908. Combined RECONNECT Phase 3 analysis, n=1,247 premenopausal women with acquired, generalized HSDD. Statistically significant improvement in FSFI-D (sexual desire) and in FSDS-DAO item 13 (distress from low desire) versus placebo. Effect sizes were modest. Industry funded. PMID 31135729.
- Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Earlier Phase 2 intranasal bremelanotide work in men with erectile dysfunction, published in 2004. Program did not proceed to FDA approval for that indication, in part because of blood-pressure signals with the intranasal formulation.
- Clayton AH et al. Supportive open-label extension data from the RECONNECT program, continuing the safety and tolerability profile in women who chose to continue after the blinded phase.
What the research does not show
The research does NOT show:
- Benefit in postmenopausal women. The Phase 3 trials enrolled premenopausal women only. The label reflects that.
- Benefit in men with erectile dysfunction. The earlier intranasal Phase 2 program in men was discontinued. There is no Phase 3 FDA-approved indication for male sexual dysfunction.
- Benefit for general-purpose libido in people without the diagnosed HSDD phenotype. The trials were not designed to answer that question, and the effect size in the approved population was modest to begin with.
- Safety in people with uncontrolled hypertension or known cardiovascular disease. The label carries contraindications and warnings on this point based on observed transient blood-pressure increases.
- Long-term daily or chronic use. The product is an on-demand autoinjector, not a daily therapy, and the pivotal trials were run that way.
Known safety signals in humans
The most common adverse events in the RECONNECT trials were nausea (about 40 percent of treated women, and the most common reason for discontinuation), flushing (about 20 percent), injection-site reactions, and headache. A smaller subset reported focal hyperpigmentation, consistent with melanocortin-1 receptor activity (the mechanism Melanotan peptides rely on for tanning).
The label warns about transient increases in blood pressure (mean increases roughly 1.9/1.2 mmHg in trials) and a compensatory decrease in heart rate. Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease, and use is limited to no more than once per 24 hours and no more than eight times per month. The full label also describes focal pigmentation changes that may persist after stopping.
FDA and legal status in the US
Vyleesi is the only FDA-approved form of bremelanotide. The approved product is a single-use subcutaneous autoinjector, prescribed on-demand, for one specific condition in one specific population: acquired, generalized hypoactive sexual desire disorder in premenopausal women. Every other use is off-label, which is a legal category of physician-directed care, not a regulatory endorsement.
The research-use-only PT-141 that dominates the online conversation is a separate situation. Those vials are not pharmacy products, carry no identity or purity assurances, and are not what the RECONNECT trial record applies to. The FDA has repeatedly warned consumers against research-use-only peptides sold for self-administration, and bremelanotide sits squarely inside that warning class when purchased outside the approved pathway.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for PT-141 specifically
PT-141 has a specific identity problem that most peptides do not: its parent molecule is Melanotan II, a tanning peptide with its own research-use-only market and its own safety concerns. Material sold online as PT-141 has, in documented analytical surveys, sometimes been mislabeled Melanotan II or a blend of both. The two compounds share melanocortin activity but differ in receptor selectivity and in the risk profile the FDA reviewed.
The other wrinkle is the dosing-form problem. The approved product is a pre-filled subcutaneous autoinjector with a known quantity of sterile drug. A research-use-only vial of lyophilized powder is a different artifact with no identity testing, no sterility assurance, and no real-world equivalence to the RECONNECT trial product, even when the label claims otherwise.
Cost reality
Brand-name Vyleesi list pricing in the US typically runs several hundred dollars for a small pack of single-use autoinjectors, with wide variation depending on insurance coverage and manufacturer programs. Out-of-pocket costs for uninsured patients can be meaningfully higher than the list price suggests. Research-use-only PT-141 vials sell online for a small fraction of that, which is the economic gradient that drives the gray market.
Cheaper is not safer. Cheaper is very often a different product than the label claims, and for a melanocortin-active peptide with documented blood-pressure effects, identity and purity are not details.
Questions worth asking any source
- Is this a pharmacy-dispensed Vyleesi autoinjector against a valid prescription from a licensed clinician, or is it a research-use-only vial?
- If the product is not branded Vyleesi, what is the manufacturer lot number and where is the GMP facility that made it?
- Is there a certificate of analysis from an independent third-party laboratory confirming the identity is bremelanotide and not Melanotan II or a blend?
- Does the product carry the FDA-approved prescribing information, including the cardiovascular contraindications and the eight-doses-per-month limit?
- Is the seller willing to ship without a prescription? If yes, that answer alone tells you what kind of operation you are dealing with.
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used PT-141. The approved indication does not apply to me, and the off-label case for men is weaker than the marketing suggests. The earlier intranasal Phase 2 program in men with erectile dysfunction was discontinued, and there is no Phase 3 registration record for male sexual dysfunction that I can point a reader to.
What I do take seriously is that RECONNECT is a real Phase 3 dataset, and bremelanotide cleared the FDA’s efficacy-and-safety bar for the population it was studied in. That is rare on my list. The effect size was modest, not transformative, and the nausea rate in the trial arm was high. Readers who round “FDA approved” to “strongly effective” usually have not read the primary numbers.
The off-label conversation is where my skepticism lives. A peptide with documented transient blood-pressure effects, a high nausea rate, and a narrow approved population is not a casual lifestyle intervention. I would want a clinician in that loop, especially for anyone with a cardiovascular history, a history of hypertension, or a family history of either.
For a curious reader, read Kingsberg 2019 and the Vyleesi prescribing information before you read anything else about PT-141. For someone considering it for the approved indication, the pharmacy pathway is straightforward and a clinician conversation is the normal next step. For someone looking at research-use-only PT-141 for off-label reasons, the identity-testing and cardiovascular-risk conversations are the ones I would want to have first.
Questions to ask your doctor
If you are considering PT-141, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- Based on my history and current cardiovascular status, am I actually a candidate for a melanocortin-active peptide, given the transient blood-pressure effects on the Vyleesi label?
- If we are talking about the approved indication, do I actually meet the diagnostic criteria for acquired, generalized HSDD that the RECONNECT trials enrolled, or am I thinking about this for a different reason the evidence base does not cover?
- What is your plan for monitoring my blood pressure and heart rate, and at what point would you want me to stop and contact you?
- If nausea is the dominant side effect in the trial record, what practical steps would you recommend for managing it, and at what severity should I discontinue?
- I have read that pigmentation changes can occur and may persist. How would you counsel me on that risk, and are there skin-history factors that would make you hesitate?
- If I am interested in this for an off-label reason rather than the approved indication, how do you weigh prescribing it given that the Phase 3 record does not cover my population?
What to do next
Read RECONNECT and the label
Start with Kingsberg 2019 in Obstetrics and Gynecology and the Vyleesi FDA prescribing information. Both are free to read and set a clean baseline.
Open the primer →Go to a real clinician
If the approved indication applies to you, the pharmacy pathway is straightforward. Bring the visit-prep packet and have the cardiovascular-history conversation out loud.
Get the packet →Pharmacy, not research chemical
The Phase 3 evidence applies to pharmacy-dispensed Vyleesi. It does not automatically apply to research-use-only vials that may or may not contain the molecule on the label.
Open the checklist →Sources
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstetrics and Gynecology. 2019;134(5):899-908. Industry funded (AMAG Pharmaceuticals, Palatin Technologies). PMID 31135729.
- Clayton AH, Althof SE, Kingsberg S, et al. Supportive RECONNECT open-label extension and integrated safety analyses. Journal of Women’s Health. 2016 and follow-up publications. Industry funded.
- Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. “Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.” International Journal of Impotence Research. 2004;16(2):135-142. PMID 14999221.
- FDA Prescribing Information, Vyleesi (bremelanotide injection). Vyleesi label (2019).
- FDA Press Announcement. “FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women.” June 21, 2019.
- Palatin Technologies and AMAG Pharmaceuticals corporate disclosures, 2019-2020, covering the transfer of Vyleesi rights back to Palatin.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
Melanotan II
The parent peptide PT-141 was derived from. A tanning peptide with case-report-level safety signals and no Phase 3 record. Read alongside for the full melanocortin story.
Afamelanotide
The other FDA-approved melanocortin peptide, approved for a rare photosensitivity disorder. Different indication, same receptor family, useful comparison for the melanocortin class.
Oxytocin
A separate neuropeptide with its own intranasal and off-label use discourse. Different mechanism, similar pattern of internet claims running ahead of the approved indications.